TORONTO, Ontario and HAIFA, Israel, May 19, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, today announced that the Korean Ministry of Intellectual Property (“MOIP”) has issued a Notice of Patent Grant for a patent application covering ExoPTEN, the Company’s lead therapeutic candidate.
The patent application covers key aspects of ExoPTEN, including the use of exosomes as a natural drug delivery system to carry PTEN-targeted therapeutic cargo for the treatment of nerve injury.
Dr. Lior Shaltiel, CEO of NurExone, commented: “This Notice of Patent Grant in South Korea further strengthens our global intellectual property portfolio and supports the advancement of ExoPTEN towards clinical development and commercialization. ExoPTEN is central to our drug-development strategy targeting significant unmet needs, including spinal cord injury and optic nerve damage.”
The Korean patent further strengthens NurExone’s expanding international ExoPTEN patent portfolio, which already includes granted patents in the United States, Japan, Israel, and Russia, as well as pending applications across multiple jurisdictions, including the European Union, China, Hong Kong, India, Israel (Continuation of IL277605), and Thailand.